Pfizer and Bristol-Myers Squibb to present Eliquis data at ACC.16

Pfizer and Bristol-Myers Squibb have released the 17 abstracts that the two companies will present at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16) in Chicago on April 2-4.

The data to be presented will revolve around the use of Eliquis to decrease the risk of stroke in patients who have nonvalvular atrical fibrillation (NVAF), as well as to treat patients suffering from venous thromboembolism (VTE).

Included in the abstracts will be new data from the ARISTOTLE and AMPLIFY Phase 3 clinical trials and the reflective analysis of real-world data, which is part of the ACROPOLIS (Apixaban Experience Through Real World Population Studies). ACROPOLIS is a worldwide real-world data research program developed to study the safety and efficacy of Eliquis in routine clinical procedure.

The clinical trial data presented by the Pfizer and Bristol-Myers Squibb Alliance will help to appraise the effectiveness and safety of Eliquis under the controlled circumstances of the trials. The real-world data will provide a look into the usages of Elquis for its accepted suggestions in routine clinical practice.